[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621653":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":44,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"University of St.Gallen","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Prediabetic",null,"Adults aged ≥45 years with BMI ≥25 kg\u002Fm².\n\nFPG 5.6-6.9 mmol\u002FL and\u002For HbA1c 5.7-6.4% (clinical prediabetes thresholds).\n\nNo known type-2 diabetes diagnosis.",{"label":13,"type":10,"description":14,"interventionNames":10},"Normoglycemic","Adults aged ≥45 years with BMI ≥25 kg\u002Fm². FPG \\\u003C5.6 mmol\u002FL and HbA1c \\\u003C5.7% (normoglycemic; no prediabetes). No known type-2 diabetes diagnosis.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Mia Jovanova, Dr.","CONTACT","+41 44 632 05 41","mia.jovanova@unisg.ch",[22],{"facility":23,"status":24,"city":25,"state":10,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"HOCH Health and School of Medicine, University of St. Gallen","RECRUITING","Sankt Gallen","9000","Switzerland","CH",{"type":30,"coordinates":31},"Point",[32,33],9.37477,47.42391,{"lat":33,"lon":32},[36,37,38,40,42],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":10},{"name":10,"role":18,"phone":10,"phoneExt":10,"email":20},{"name":17,"role":39,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":41,"role":39,"phone":10,"phoneExt":10,"email":10},"Tobias Kowatsch, Prof. Dr.",{"name":43,"role":39,"phone":10,"phoneExt":10,"email":10},"Michael Brändle, Prof. Dr. med",{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100621653","glucose-observation-and-wearable-use-for-prevention-100621653",false,"NCT07373418","Glucose Observation and Wearable Use for Prevention","GLOW UP: A Single-Center Observational Study Developing Digital Biomarkers for Prediabetes Screening and Lifestyle Phenotyping","GlowUp","Inclusion Criteria:\n\n* Citizens or residents of Switzerland who are German-speaking (main place of living or employment in Switzerland).\n* Age ≥45 years.\n* BMI ≥25 kg\u002Fm² (overweight or obese).\n* Regular access to a smartphone (iOS or Android) with a data plan.\n* Able to use smartphone applications.\n* Able to walk independently.\n\nExclusion Criteria:\n\n* History of stroke, heart disease, renal failure, cancer, or diabetes (type 1 or type 2).\n* Past vascular bypass surgery or angioplasty.\n* Current or planned use of glucose-lowering medications during the upcoming 4 weeks (e.g., GLP-1 receptor agonists, metformin).\n* Pregnant or breastfeeding.\n* Relevant skin conditions at wearable placement sites (e.g., upper arm).\n* BMI \\\u003C25 kg\u002Fm² confirmed at enrollment.\n* FPG ≥7.0 mmol\u002FL and\u002For HbA1c ≥6.5% (newly identified type 2 diabetes); Individuals who meet type-2 diabetes criteria at enrollment, based on Swiss\u002FADA diagnostic criteria will be informed of blood test results and referred to a GP. These individuals will be deemed ineligible and excluded from the study.",true,"ALL","45 Years",{"count":58,"type":59},200,"ESTIMATED","OBSERVATIONAL","The GLOW UP study is a single-center, prospective, observational case-control study conducted in St. Gallen, Switzerland. The primary aim of the study is to examine to what degree lifestyle data collected from wearable devices and a smartphone app can identify individuals with prediabetes (vs. normoglycemic) in a real-world setting. The study also aims to characterize variability in lifestyle and glycemic patterns and to examine how between- and within-person differences relate to diabetes risk; to identify personalized predictors of early metabolic dysregulation. The study also evaluates new image-based meal tracking algorithms for predicting glycemic control and examines how reminder messages influence adherence to a \\~4-week meal logging protocol.\n\nThe study aims to enroll 200 adults aged 45 years and older with a BMI of at least 25 kg\u002Fm² and no known diagnosis of diabetes, including 100 participants with prediabetes and 100 normoglycemic (metabolically healthy) controls. Participants will be classified at the baseline visit using HbA1c and fasting plasma glucose (FPG) tests, with prediabetes defined as HbA1c 5.7-6.4% and\u002For FPG 5.6-6.9 mmol\u002FL, and normoglycemia defined as HbA1c \\\u003C5.7% and FPG \\\u003C5.6 mmol\u002FL, following clinical standards. During the \\~4-week observational period, participants will be asked to wear a smart ring, a wrist-worn smartwatch, and a blinded continuous glucose monitor (CGM). Participants will be asked to log\u002Ftake-images of their meals via a study app and to complete brief questionnaires (e.g., tracking mood, stress, and contextual meal annotations) via ecological momentary assessments. FPG and HbA1c samples will be collected at baseline to classify participants as prediabetic or normoglycemic, and again at follow-up (\\~4 weeks), which will serve as the primary outcome to evaluate associations between lifestyle and wearable-derived data and diabetes risk status.",[63],"Prevention","2026-01-19",{"date":66,"type":67},"2026-01-28","ACTUAL",{"date":69,"type":67},"2025-12-08",{"date":71,"type":59},"2027-01",{"name":5,"class":6},1]